In our mission to improve the lives of people living with cancer, Clovis Oncology is devoted to fulfilling the promise of precision cancer medicine. We strive to create targeted therapies to better serve patients and guarantee that the right medication reaches the right person. Clovis Oncology directs development programs to particular subsets of cancer patients and concurrently develops, with partners, for those indications that require them, diagnostic tools aimed at targeting a developing compound to the population most likely to benefit from its use. Clovis remains focused on its liquidity position and acknowledges that it will need to raise additional capital in the short term to finance its operating plan for the next 12 months and continue as a going concern.
FAP-2286 is the first peptide-targeting radionuclide therapy (PTRT) and imaging agent targeting fibroblast activating protein (FAP) entering clinical development and is the lead candidate in the Clovis Oncology TRT development program. The company concentrates on licensing or acquiring rights to oncology compounds at all stages of clinical development. Clovis is constructing a portfolio of novel targeted radiotherapies for cancer treatment and imaging, including its lead candidate, FAP-2286, an investigational peptide-targeting radionuclide therapeutic agent (PTRT) and an imaging agent, as well as three additional compounds under discovery. Clovis Oncology competitors include Arena Pharmaceuticals, Crown Bioscience International, SpiroGen, Cytochroma, Novexel and 12 others.
To the extent that the statements contained in this news release are not descriptions of historical facts related to Clovis Oncology, they are forward-looking statements that reflect management's current beliefs and expectations made pursuant to the private securities safe harbor provisions Litigation Reform Act 1995. With sales of the PARP inhibitor Rubraca rucaparib sequentially declining in 2Q22, as well as compared to 2Q21, Clovis Oncology Inc. It focuses on radiation modulators for oncology, medical imaging and medical countermeasures. Clovis remains focused on its liquidity position and is committed to raising additional capital in the short term to finance its operating plan for the next 12 months and beyond. Clovis Oncology investors include Citadel, Abingworth, New Enterprise Associates, Frazier Healthcare Partners, Versant Ventures and 5 others. The accompanying condensed consolidated financial results have been prepared on a basis that assumes that Clovis will continue as a going concern.
Clovis Oncology is developing cancer treatments for certain patients who have metastatic pancreatic cancer, non-small cell lung cancer, and several solid tumors.
Clovis Oncologyis headquartered in Boulder, Colorado, with additional offices in the United States and Europe. A more detailed description of the risks and uncertainties can be found in Clovis Oncology's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its reports on Form 10-Q and Form 8-K.Clovis Oncology is a biopharmaceutical company dedicated to developing targeted therapies for people living with cancer. The company has a strong focus on precision medicine – creating treatments tailored specifically for individual patients – as well as developing diagnostic tools that can identify which patients are most likely to benefit from a particular therapy.
In addition to their own research programs, they also license or acquire rights to existing oncology compounds at all stages of clinical development. Clovis Oncology’s lead candidate is FAP-2286 – a peptide-targeting radionuclide therapy (PTRT) and imaging agent targeting fibroblast activating protein (FAP). This compound is currently undergoing clinical trials and has shown promising results so far. The company also has three additional compounds under discovery which could potentially be used in combination with FAP-2286 or as stand-alone treatments.
Clovis Oncology’s competitors include Arena Pharmaceuticals, Crown Bioscience International, SpiroGen, Cytochroma, Novexel and 12 others. The company’s investors include Citadel, Abingworth, New Enterprise Associates, Frazier Healthcare Partners, Versant Ventures and 5 others. Clovis Oncology’s headquarters are located in Boulder, Colorado with additional offices in the United States and Europe. The company is committed to raising additional capital in order to finance their operating plan for the next 12 months and beyond.
In conclusion, Clovis Oncology is dedicated to improving the lives of people living with cancer through precision medicine. Their focus on developing targeted therapies as well as diagnostic tools has enabled them to create treatments tailored specifically for individual patients. With their headquarters located in Boulder Colorado and additional offices throughout the United States and Europe they are well positioned to continue their mission of providing innovative treatments for those living with cancer.